Tocilizumab as treatment for COVID-19: A systematic review and meta-analysis

Table 3 outcome of patients treated with tocilizumab therapy

Ref.	N° TCZ administered (median doses)	Death %	Dismissed %	Median hospitalization (d)	TCZ AEs %	Comparison with other medications or no TCZ	NOS Scale	ROBIN risk
Alattar et al[11], 2020	1	12	36 (from ICU)	-	Anemia 64; ALT ↑ 44	HR for discharge from ICU 0.64 (0.37-1.11)	8	Low
Alberici et al[12], 2020	1	33	16	-	-	-	6	Moderate
Capra et al[13], 2020	1	8	92	12.5	-	OR for OS 0.036 (0.07-0.18)°	7	Low
Colaneri et al[14], 2020	2	23.8	85.7 (from ICU)	2	0	OR for OS 0.78 (0.06-9.34); OR for ICU 0.11 (0-3.38)	7	Low
Hassoun et al[15], 2020	1	22	55	13.5 (n = 7)	-	-	5	Low
Klopfenstein et al[16], 2020	1 or 2	25	55	13	-	OR for OS and ICU admission 0.36 (0.1-1.3) and 0.03 (0.002-0.56); OR for mechanical vent 0.05 (0.003-0.93)	5	Low
Luo et al[17], 2020	1	20	-	-	-	-	5	High
Quartuccio et al[18], 2020	1	9.5	28.5	-	-	OR for OS 14.5 (0.76-278.3); OR for ICU admission 220.9 (12.7-3826.1)	8	Moderate
Sciascia et al[19], 2020	1 (2 in 82.5%)	11	-	-	-	-	6	Moderate
Toniati et al[20], 2020	1 (2 in 87%)	20	15	-	Septic shock (n = 2), GI perforation (n = 1)	-	8	Low
Xu et al[21], 2019	1 (2 in 14.3%)	0	100	15.1	-	-	5	Moderate
Ramaswamy et al[22], 2020	1 (2 in 38%)	14.3	-	-	-	HR for OS 0.25 (0.07-0.9)	5	Moderate
Rimland et al[23], 2020	1	27	18	18	-	-	7	Low
Sanchez-Montalva et al[24], 2020	1	26.8	41.5	-	-	-	6	Low
Wadud et al[25], 2020	-	38.6	-	-	-	OR for OS 0.58 (0.25-1.32)	6	Moderate
Campochiaro et al[26], 2020	1 (2 in 28%)	15	63	13.5	SAEs (25)	OR for OS 0.38 (0.11-1.27); OR for ICU admission 0.33 (0.13-8.5)	8	Low
Morena et al[27], 2020	-	27	61	-	AST/ALT ↑ 29, PLT 14, neutropenia 6, rash 2	-	8	Low
Kimmig et al[28], 2020	1 (2 in 10.7%)	42.9	25	-	Infections 71.4	OR for OS 2.25 (0.75-2.24)	6	Moderate
Roumier et al[29], 2020	1	10	20	-	-	OR for OS 0.25 (0.05-1.03); OR for ICU 0.17 (0.06-0.48)	7	Low
Ip et al[30], 2020	1 (78%)	46	-	-	Bacteriemia (13), secondary pneumonia (9)	OR for OS 0.66 (045-0.99)	8	Low
Perrone et al[31], 2020	1 (59.8), 2 (54.5)	20	-	-	26.4 G3-5; 14.4 G1-2	OR for 30-d OS 0.7 (0.41-1.22) and 1.22 (0.86-1.92) in phase 2 and validation cohort	8	Low
Perez-Tanoira et al[32], 2020	-	27.7	-	-	-	OR for OS 1.015 (0.47-2.18)	5	Moderate
Somers et al[33], 2020	1	18	56	20.4	Superinfection (54)	OR 0.39 (0.18-0.82)	8	Low
Heili-Frades et al[34], 2020	-	22.4	-	-	-	-	6	Moderate
Issa et al[35], 2020	1	10	-	11 (ICU)	-	-	5	High
Moreno-Garcia et al[36], 2020	-	10.3	84.4	-	-	OR for ICU 0.3 (0.12-0.71) and OR for OS 0.52 (0.21-1.29)	5	Moderate
Ayerbe et al[37], 2020	-	21.1	-	-	-	OR for OS 1.9 (1.44-2.51)	5	High
Borku Uysal et al[38], 2020	2	0	100	-	-	-	6	Moderate
Fernandez-Cruz et al[39], 2020	-	-	-	-	-	OR for OS 0.69 (0.41-1.19)	5	High
Garibaldi et al[40], 2020	-	5	-	-	-	OR for OS 1.14 (0.46-2.81)	5	Moderate
Martínez-Sanz et al[41], 2020	1	23	-	13	-	OR for OS 2.19 (1.54-3.1)	5	Low
Petrak et al[42], 2020	1 (84.8), 2 (15.2)	28.3	48.3	-	-	-	5	Moderate
Rossi et al[43], 2020	1	28.9	-	-	-	HR for OS 0.29 (0.17-0.49)	8	Low

-: Not availble; NOS: Nottingham-ottawa-scale; ROBIN: Risk of bias of non-randomized studies; ALT: Alanine aminotransferase.